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Abstract
Background: Malaria infection is still widespread in some parts of the world and threatens the lives of millions of
people every year. Vaccines, especially oral vaccines are considered to be effective in reducing the burden of malaria
morbidity and mortality. By using recombinant technology, suitable oral hosts could serve as antigen delivering
vehicles in developing oral vaccines. This study was aimed towards designing and computational analysis of a fusion
protein consisting of Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS) fused to
human interleukin-2 (IL-2) and M cell-specific peptide ligand (Co1), as a step toward developing a vaccine candidate.
Results: To our best knowledge, the three dimensional (3D) structure of CelTOS is not reported in protein database.
Therefore, we carried out computational modeling and simulation in the hope of understanding the properties and
structure of PfCelTOS. Then we fused IL-2 to PfCelTOS by a flexible linker and did in silico analysis to confirm the proper
folding of each domain in the designed fusion protein. In the last step, Co1 ligand was added to the confirmed fusion
structure using a rigid linker and computational analysis was performed to evaluate the final fusion construct.
One structure out of five predicted by I-TASSER for PfCelTOS and fusion constructs was selected based on the
highest value for C-score. Molecular dynamics (MD) simulation analysis indicated that predicted structures are
stable during the simulation. Ramchandran Plot analysis of PfCelTOS and fusion constructs before and after MD
simulation also represented that most residues were fallen in favorable regions.
Conclusion: In silico study showed that Co1-(AEEEK)3- IL-2-(GGGGS)3-PfCelTOS construct has a constant structure and
the selected linkers are effectively able to separate the domains. Therefore, data reported in this paper represents the
first step toward developing of an oral vaccine candidate against malaria infection.
Keywords: Malaria, Fusion protein, Molecular modeling, Molecular dynamics simulations
* Correspondence: Ofoghi@irost.ir
Department of Biotechnology, Iranian Research Organization for Science and
Technology, Tehran, Iran
© 2016 Shamriz and Ofoghi. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Shamriz and Ofoghi BMC Bioinformatics  (2016) 17:71 
DOI 10.1186/s12859-016-0918-8
Background
Infectious diseases are the leading cause of death all over
the world [1, 2]. Malaria, also called plasmodium infec-
tion, is one of the most important human infectious dis-
eases threatening the lives of millions of people every year.
According to WHO malaria report, globally, about 3.2 bil-
lion people in 97 countries and territories are at risk of be-
ing infected with malaria, and 1.2 billion are at high risk
[3]. Although the disease has been eradicated in most
areas, it’s still widespread in some regions [3]. The biggest
challenges in controlling malaria disease are the emer-
gence of anti-malarial drug resistance and insecticide re-
sistance in parasite and mosquito, respectively [4–6].
Therefore, there is an urgent need to develop novel inter-
vention strategies such as vaccines to reduce the burden
of malaria morbidity and mortality. Malaria is most com-
mon in poor and developing regions of the world and has
a strong negative effect on economic growth [7]. Oral im-
munogenicity has opened new avenues for the development
of vaccines potentially effective in reducing the burden of
diseases especially in low-income and developing countries.
Oral vaccines are Low cost, easily administered (needle-
free), in most cases capable of being stored and transported
without refrigeration (Non-Refrigerated) and painless [8].
In contrast to injected vaccines, oral vaccines target muco-
sal surfaces, which cause stimulation of systemic as well as
mucosal immune responses [9–11]. Considering the fact
that most pathogens enter the body through mucosal sur-
faces, mucosal immune system provides the first line of
defense against invading bacteria and viruses. Therefore,
the simultaneous induction of systemic and mucosal
immunity offers an ideal strategy to fight infectious dis-
eases. Despite many advantages that oral vaccines have,
only limited numbers of them have been approved for
human commercial use and yet significant challenges
must be overcome to make oral vaccines closer to real-
ity [12]. One of the challenges is the complexity of mu-
cosal immune system that must discriminate between
harmless and dangerous antigens. One way to over-
come this problem is to use adjuvants. Oral adjuvants
offer exciting possibilities for the formulation of oral
vaccines [13–15].
During the past decades considerable progress in re-
combinant DNA technology has led to the development
of fusion proteins. Fusion proteins are novel biomole-
cules obtained by genetically fusing two or more genes
that originally code for separate proteins. Thereby fusion
proteins have distinct functions derived from each of
their domains. Fusion proteins have wide applications in
industry and pharmaceutical protein production.
The general objective of the current study was the de-
sign and computational analysis of a fusion protein con-
sisting of Plasmodium falciparum cell-traversal protein
for ookinetes and sporozoites (PfCelTOS) fused to human
interleukin-2 (IL-2) and M cell-specific peptide ligand
(Co1), as a step toward developing a candidate recombin-
ant oral vaccine against malaria. CelTOS is a protein that
mediates malarial invasion into its hosts (both vertebrate
and mosquito) and is required for effective malaria infec-
tion [16–18]. On the other hand, CelTOS amino acid se-
quence is highly conserved among the Plasmodium
species. CelTOS highly conserved amino acid sequence
and vital role for malaria infection indicate its important
function across all species [19]. Therefore, targeting the
immune response to this highly conserved and crucial
protein and interfering with its biological function could
possibly result in protection against infection by heterol-
ogous species of Plasmodium [19].
In the designed construct, human interleukin 2 (IL-2) is
thought to act as mucosal adjuvant. It should be consid-
ered that the type of desired immune response (cellular or
humoral) will influence the choice of adjuvants for
immunization regimens [20]. In case of malaria disease,
parasites and infected red blood cells which activate den-
dritic cells through pattern recognition receptors (PRRs)
are phagocytosed and their antigens are presented to T
cells. PRR signaling causes the secretion of cytokines that
initiate the inflammation that underlies malaria pathogen-
esis and direct TH1 cell to differentiate. TH1 cells help B
cells differentiation and antibody secretion and also se-
crete IFN-γ, which activates macrophages that phagocyt-
ose opsonized parasites and infected red blood cells and
subsequently kill them by NO- and O2-dependent path-
ways. Inflammation induces expression of endothelial ad-
hesion molecules to which infected red blood cells bind.
Finally the secretion of anti-inflammatory cytokines from
macrophages and regulatory populations of T cells cur-
tailed the Inflammation [21]. To the best of our under-
standing, adjuvants that increase the TH1 response are
more appropriate in malaria vaccine development. Here
we focus on human interleukin 2 (IL-2) as mucosal adju-
vant. IL-2 has a central role in the cascade of events in-
volved in immune responses and can function as a vaccine
adjuvant to increase the immune response to vaccine im-
munogens [20, 22–26].
Specific advantages of IL-2 as adjuvant for malaria vac-
cine are as follow:
1) IL-2 stimulates T cells to secrete INF-γ. INF-γ is
known as immune interferon due to activating
macrophages and enhancing phagocytic activity
which leads to activation of immune responses. On
the other hand, INF-γ results in the expression of
MHCI and MHCII molecules on the surface of infected
cells and antigen presenting cells, respectively, therefore
enhancing antigen presenting and immune system
activity. In addition, INF-γ activates the secretion of
IgG and its subclasses by effecting on B lymphocytes
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(The positive effect of INF-γ on immune responses to
malaria parasite is discussed above).
2) Activation of T cells under the influence of IL-2
leads to the secretion of cytokines such as IL-10.
Unlike many other interleukins, IL-10 inhibits
macrophage activity and secretion of IL-1, IL-12
and TNF. IL-12 acts as inducer for INF-γ and is an
effective factor in cellular and innate immune responses
against intracellular microbes. Inhibition of IL-12 leads
to inhibition of INF-γ production. In fact, IL-10 is well
known as the inhibitor of immune responses, especially
responses that are set up by macrophages, thereby
immune responses are terminated. As mentioned
above, the enhancement of inflammation and
thereby endothelial adhesion of blood vessels is
one of the outcomes of immune system responses
to malaria parasite and malaria vaccine. In this
case, repressive role of IL-10 prevents excessive
inflammation.
Although reported studies have indicated the potential
of cytokines as mucosal adjuvants, in order to increase
the probability of vaccine candidate binding to intestinal
cells, we adopted another strategy. Co1 is a peptide lig-
and that promotes the binding of ligand-fused antigen to
human M-like cells and has also comparable levels of
adjuvant activity to Cholera Toxin (CT) [27]. Conjuga-
tion of Co1 to the designed construct should result in
delivery of antigen to M cells.
Since most of the biological functions of proteins de-
pend upon their 3D structure, in designing multi domain
recombinant proteins, proper folding, stability and inter-
action between domains must be considered. Fusion
proteins are much more susceptible to misfolding than
single-domain proteins due to the interaction between
their different peptide domains. Therefore, in silico ana-
lysis of multi domain proteins is an indispensible stage
in recombinant protein production projects.
Attempts to model the structure of proteins on the
computer began about 30 years ago. Since that time our
understanding of protein structure and dynamics has
significantly increased and now Protein Data Bank (PDB)
contains more than 10,000 high resolution protein struc-
tures. Valuable 3D models of a protein that has a clear se-
quence homology to known proteins can be predicted by
homology modeling method. However, even in cases
where there is no sequence homology, threading methods
relate protein sequences to a library of known structures
and predict the likely protein structure. The crystallo-
graphic structure of CelTOS has not been reported yet.
In the present study, we carried out a molecular mod-
eling study of PfCelTOS protein and designed fusion
proteins using iterative threading assembly refinement
(I-TASSER) to obtain their 3D structures. Then energy
minimization and molecular dynamics (MD) simula-
tion were run to refine the models. The simulations of
PfCelTOS and fusion proteins were performed for long
time duration of 10 ns and the obtained structures
were analyzed to verify further.
Methods
Sequence retrieval and fusion protein construction
The amino acid sequences of PfCelTOS, human IL-2 and
M cell-targeting ligand, Co1, were retrieved from UniProt
(PfCelTOS id: Q53UB8; human IL-2 id: P60568). Amino
acid sequences were used to design fusion protein con-
struct. The designed construct consisted of PfCelTOS and
human IL-2 mature parts linked together by a flexible
linker, whereas Co1 is linked to this construct through a
rigid (helical) linker.
Primary structural analysis
Expasy’s Prot Param server [28] was used to study the
physiochemical characters of PfCelTOS and designed fu-
sion constructs such as theoretical isoelectric point (pI),
molecular weight, molecular formula, total number of
positive and negative residues, instability index [29], ali-
phatic index [30] and grand average hydropathicity
(GRAVY) [31]. The instability index provides an esti-
mate of a protein’s stability in vitro. Proteins with in-
stability index smaller than 40 are predicted as stable. A
value above 40 indicates that the protein may be
unstable.
The aliphatic index of a protein is regarded as a posi-
tive factor for the increase of thermostability of globular
proteins and is mainly defined as the relative volume oc-
cupied by aliphatic side chains (alanine, valine, isoleu-
cine and leucine). The GRAVY score is calculated as the
sum of hydropathy values of all the amino acids, divided
by the number of residues in the sequence.
Secondary structure prediction
Secondary structure elements of PfCelTOS and designed
fusion proteins were determined using Phyre2 [32] and
I-TASSER [33] online servers.
Three-Dimensional (3D) model prediction
The 3D structure of PfCelTOS and fusion proteins were
modeled using I-TASSER online server. The raw amino
acid sequences of PfCelTOS and fusion proteins were
uploaded in FASTA format to I-TASSER server. Tertiary
structures were predicted in PDB format. The results
generated five top models for each entry which the one
with the highest confidence score (c-score) represented
the best model and was the structure selected for this
study [33].
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Structure Validation
Visualization was carried out by PyMOL version v1.7.2
software [34]. Traceable structural errors were proofed
and global charges replaced by Vega ZZ version 3.0.5.12
software [35]. Ramachandran plots were calculated by
RAMPAGE Ramachandran Plot Assessment [36]. Hydro-
pathicity index were calculated by Marvin view version
14.7.7 software (http://www.chemaxon.com). Molecular
dynamics were performed by GROMACS version 5.0.1
software [37, 38]. PDB file format were analyzed for MD
approaches-molecular dynamics algorithm including an
initial cubic salvation with 3 point simple water model,
followed by ionization and neutralization of simulation
cube with Na and Cl ions. Geometry optimization was
performed with constrain method. This procedure contin-
ued with two separate temperature and pressure uncon-
strained global dynamics. Final unconstrained dynamics
performed with coupled temperature (300° K) and pres-
sure (1 bar) for 10 ns. A schematic sketch of molecular dy-
namics procedure is presented in Table 1.
Fig. 1 Screening procedure of modeled structures
Table 1 A schematic sketch of molecular dynamics procedure
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Analysis of simulation
After the simulation had finished, the output data were
analyzed according to Energy (kinetic, potential & total
energy), root-mean-square deviation (RMSD), Gyration
radius and H bond formation/deformation. The follow-
ing plot is represented as screening procedure of mod-
eled structures (Fig. 1).
Results and discussion
To our knowledge, the crystallographic structure of Cel-
TOS has not been reported in the protein database.
Therefore, in silico analysis of CelTOS 3D structure
could be of benefit in predicting its probable structure.
Computer prediction and simulation methods can be
used to generate representative conformations of a mol-
ecule in equilibrium and provide a picture of the way in
which a molecule changes from one configuration to an-
other [39]. Therefore, we carried out computational
modeling and simulation in the hope of understanding
the properties and structure of PfCelTOS. Then we
fused IL-2 to PfCelTOS by a flexible linker and did in
silico analysis to confirm the proper folding of each do-
main in the designed fusion protein. In the last step,
Co1 ligand was added to the confirmed fusion structure
using a rigid linker and computational analysis was per-
formed to evaluate the final fusion construct.
Primary structure analysis
The primary structure of PfCelTOS (accession number
Q53UB8) is composed of 182 amino acid residues,
encoded by 546 nucleotides. A fragment of 9 amino
acids at the N-terminal is a signal peptide and the next
173 amino acids fragment is a mature peptide. Human
IL-2 (accession number P60568) composed of 153 amino
acid residues, encoded by 459 nucleotides. A fragment
of 20 amino acids at the N-terminal was found to be a
signal peptide and the remaining 133 amino acids frag-
ment was a mature peptide [40]. The 173 amino acids
fragment of PfCelTOS (mature part) and 133 amino
acids fragment of IL-2 were used to design the fusion
protein construct. The length of the designed construct
is 321 amino acids, which within 1 to 133 is IL-2. Amino
acids 133 to 148 (15 aa) are linker sequence, which is
(GGGGS)3. Amino acids 149 to 321 (173 aa) are PfCel-
TOS. Based on previous studies, N-terminal of IL-2 and
C-terminal of PfCelTOS seems more important in their
biological function than the other end. Therefore we de-
signed the fusion construct in a way to make free the N-
and C-terminals of IL-2 and PfCelTOS, respectively. The
Co1 ligand peptide was added to the computationally
confirmed structure of IL-2-(GGGGS)3-PfCelTOS. To
present the Co1 ligand to human M-like cells better, a
rigid linker ((AEEEK)3) was used between Co1 ligand
and designed fusion protein and the new construct was
designed as follow: Co1-(AEEEK)3- IL-2-(GGGGS)3-
PfCelTOS. Figure 2 shows schematic view of designed
fusion protein construct.
The primary structural features of PfCelTOS and two
designed fusion constructs determined by Prot Param
are summarized in Table 2. Prot Param is a tool which
allows the computation of various physical and chem-
ical parameters for a given protein. The calculated
isoelectric points (pI) for PfCelTOS, IL-2-(GGGGS)3-
PfCelTOS and Co1-(AEEEK)3- IL-2-(GGGGS)3-PfCel-
TOS were 4.58, 5.11 and 5.32, respectively, suggesting
Table 2 Properties of PfCelTOS, human IL-2 and designed constructs determined by ProtParam
Protein PfCelTOS Fusion protein1 Fusion protein2
(IL-2-linker-PfCelTOS) (Co1-linker-IL-2-linker-PfCelTOS)
No. of amino acids 173 321 348
Molecular weight 19087.4 35433.2 38176.4
Theoretical pI 4.58 5.11 5.32
Total No. of negatively charged residues (Asp + Glu) 23 38 41
Total No. of positively charged residues (Arg + Lys) 13 28 32
Formula C855H1326N212O274S4 C1581H2495N405O494S11 C1703H2691N441O530S11
Instability index 41.67 48.01 49.75
Aliphatic index 89.48 91.06 89.11
Grand average of hydropathicity (GRAVY) −0.106 −0.151 −0.172
Fig. 2 Schematic view of the designed fusion protein construct
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the presence of more negatively charged residues. Al-
though, proteins were found to be stable due to their
high aliphatic index, an instability index of more than
40 suggests instability and thus predicted that the pro-
teins were thermally unstable. The value of aliphatic
index for PfCelTOS, IL-2-(GGGGS)3-PfCelTOS and
Co1-(AEEEK)3- IL-2-(GGGGS)3-PfCelTOS were 89.48,
91.06 and 89.11, respectively, while that of instability
index were 41.67, 48.01 and 49.75. GRAVY (Grand
average hydropathy) values of PfCelTOS, IL-2-(GGGGS)3-
PfCelTOS and Co1-(AEEEK)3- IL-2-(GGGGS)3-PfCelTOS
were −0.106, −0.151 and −0.172, respectively, suggest-
ing a hydrophilicity pattern with better interaction with
water.
Secondary structure prediction
Among protein structure prediction software, the on-line
servers seem more appropriate since they have access to
all structures available in databases. Secondary structure
of PfCelTOS and designed fusion constructs were pre-
dicted by Phyre2 and I-TASSER servers. phyre2 (Protein
Homology/AnalogY Recognition Engine; pronounced as
‘fire’) is among the most popular methods for protein
structure prediction having been cited over 1500 times
and has been designed to ensure a user-friendly interface
for users inexpert in protein structure prediction methods.
Both programs established that PfCelTOS structure is
Fig. 3 I-TASSER predicted 3D structures of (a) PfCelTOS, (b) IL-2-(GGGGS)3-PfCelTOS and (c)Co1-(AEEEK)3- IL-2-(GGGGS)3-PfCelTOS
Table 3 Phyre2 prediction and analysis of secondary structure
Protein α-helix β sheets Coils
PfCelTOS 79 % 0 % 25 %
IL-2-linker-PfCelTOS 65 % 5 % 24 %
Co1-linker-IL-2-linker-PfCelTOS 63 % 5 % 27 %
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Fig. 4 Structural model refinement analysis of PfCelTOS predicted structure. a Energy plots for the molecular dynamics simulation of PfCelTOS
predicted structure. b Total RMSD, c the radius of gyration and d Hydrogen bond formation/deformation of PfCelTOS predicted structure. RMSD
of PfCelTOS stable conformation observed after the extension of a 10 ns simulation run
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Fig. 5 Structural model refinement analysis of IL-2-(GGGGS)3-PfCelTOS predicted structure. a Total, Potential and Kinetic energies for MD simulation of
IL-2-(GGGGS)3-PfCelTOS predicted structure. b Total RMSD, c the radius of gyration and d Hydrogen bond formation/deformation of IL-2-(GGGGS)3-PfCel-
TOS predicted structure
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Fig. 6 Structural model refinement analysis of Co1-(AEEEK)3- IL-2-(GGGGS)3-PfCelTOS predicted structure. a Total, Potential and Kinetic energies for
MD simulation of Co1-(AEEEK)3- IL-2-(GGGGS)3-PfCelTOS Structural model refinement analysis. b Total RMSD, c the radius of gyration and d Hydrogen
bond formation/deformation of Co1-(AEEEK)3- IL-2-(GGGGS)3-PfCelTOS predicted structure
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predominantly made of α-helices and coil–coils and there
was no significant strand in PfCelTOS. The location of
rigid linker fragment within amino acids 13–27 in Co1-
(AEEEK)3- IL-2-(GGGGS)3-PfCelTOS was shown by hel-
ical structures. Phyre2 prediction and analysis of second-
ary structure of proteins is shown in Table 3. In case of
the fusion constructs also, amount of α-helices exceeded
β-sheets. The presence of only 5 % β-sheets is related IL-2
structure (a bend created by proline residue at position 47
0f IL-2).
Three-Dimensional (3D) structure prediction
Prediction of 3D structure was performed by I-TASSER
online server using the best aligned template obtained
by searching against Protein Data Bank database. I-
TASSER (Iterative Threading ASSEmbly Refinement)
server (as ‘Zhang-Server’) is a web-based service for the
prediction of protein structures and functions. It’s free
for academic users and allows them to automatically
generate high-quality models of 3D structure of proteins
from their amino acid sequences. It detects structure
templates from PDB by threading technique. I-TASSER
is one of the most successful servers in the community-
wide CASP (Critical Assessment of protein Structure
Prediction) experiments and was ranked as the No 1 ser-
ver for protein structure prediction in recent CASP7
CASP8, CASP9, CASP10, and CASP11 experiments.
3D structure prediction by I-TASSER generates five
top models with C-scores ranging from −5 to 2. The one
with the highest C-score represents the best model. The
highest value for predicted models of PfCelTOS, IL-2-
(GGGGS)3-PfCelTOS and Co1-(AEEEK)3- IL-2-
(GGGGS)3-PfCelTOS were −2.94, −2.23 and −2.67, re-
spectively. These models were selected for this study.
The best selected model for PfCelTOS based on C-score
represented that the 3D structure is consistent with sec-
ondary structure elements generated by Phyre2. Based
on Phyre2 SS confidence, amino acids 3–15, 25–28, 32–
47, 85–112 and 122–145 are α-helices with high confi-
dence, which are also predicted as α-helix structures in
3D model of PfCelTOS generated by I-TASSER (shown
in different colors in Fig. 3). It is important to note that
further fusion protein constructs linked by other flexible
linkers were designed but the one with (GGGGS)3 linker
resulted in the best 3D structure based on C-score. Pre-
dicted model for IL-2-(GGGGS)3-PfCelTOS showed a
protein with two separate domains linked together
through a small linker. Glycine-rich peptides confer
flexibility, which allows the domains to move independ-
ently of one another while maintaining their individual
three dimensional shapes [41]. 3D structure prediction
of Co1-(AEEEK)3- IL-2-(GGGGS)3-PfCelTOS showed a
protein with three domains linked together by two small
linkers. (AEEEK)3 rigid linker keeps domains apart and
ensure a relatively rigid separation of the domain and
carrier [41]. The pre-simulated 3D structures of PfCel-
TOS and fusion proteins are shown in Fig. 3.
Structural model refinement
The structural refinement was carried out using molecu-
lar dynamics simulation as described in methods. Simu-
lation acts as a bridge between theory and experiment.
Indeed we test a theory by conducting a simulation
using the same or computationally predicted models and
provide a guess at the possible interactions between
molecules [39, 42]. Gromacs is a molecular dynamics ap-
plication developed by Groningen University. Gromacs
is able to work in the operating system Linux. The main
ability of Gromacs is to perform MD simulation and
minimization energy. However, Gromacs does not work
alone and should interact with PyMOL and Grace.
PyMOL is an application to visualize molecule structure
and Grace is an application in Linux to display graphs.
Both applications support analysis of MD simulation.
The MD simulation output data were analyzed based
on Energy (kinetic, potential & total energy), RMSD
[43], Gyration radius [44] and H bond formation/de-
formation [45]. The total energy should be constant
throughout the simulation process, as it is the sum of
kinetic and potential energy of the molecules. Kinetic
energy should be constant or following a decreasing
trend since the constant increasing of kinetic energy
level reflects the general confusion of protein structure.
Potential energy level should be increasing or constant
Table 4 The Ramchandran plot analysis of the proteins before and after MD simulation obtained by RAMPAGE Ramachandran Plot
Assessment
Proteins Favored region Allowed region Outlier region
PfCelTOS Pre-MD 57.3 % 26.3 % 16.4 %
Post-MD 74.7 % 19.4 % 5.9 %
IL-2-(GGGGS)3-PfCelTOS Pre-MD 58.3 % 22.9 % 18.8 %
Post-MD 76.4 % 17.6 % 6.0 %
Co1-(AEEEK)3-IL-2-(GGGGS)3-PfCelTOS Pre-MD 76.3 % 15.9 % 7.8 %
Post-MD 85.8 % 11.6 % 2.6 %
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Fig. 7 (See legend on next page.)
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Fig. 7 Comparative diagram depicting Ramchandran Plot analysis of PfCelTOS an fusion proteins before and after molecular dynamic simulations
(a) PfCelTOS (b) IL-2-(GGGGS)3-PfCelTOS (c) Co1-(AEEEK)3- IL-2-(GGGGS)3-PfCelTOS. The plots were analyzed by RAMPAGE Ramachandran Plot
Assessment. The general favored region and Pro-Pro favored region are indicated with dark blue color. The general allowed region and Pro-Pro
allowed region is shown in pale blue. The Glycine favored and allowed regions are shown in dark and pale orange, respectively. The disallowed
region is in white color
Fig. 8 3D structures of (a) PfCelTOS, (b) IL-2-(GGGGS)3-PfCelTOS and (c) Co1-(AEEEK)3- IL-2-(GGGGS)3-PfCelTOS after molecular dynamics simulations
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Fig. 9 Structural comparison of predicted models for (a) PfCelTOS (b) IL-2-(GGGGS)3-PfCelTOS (c) Co1-(AEEEK)3- IL-2-(GGGGS)3-PfCelTOS, obtained
before (shown in yellow) and after molecular dynamics simulations (shown in red) from different views
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to show the stability of structure. RMSD is the measure
of the average distance between the backbone atoms of
proteins. The structural refinement was carried out
using molecular dynamics simulation over the equilibra-
tion course and exhibits RMSD plots for predicted
models of PfCelTOS and fusion constructs that flattens
during 10 ns. RMSD plots indicated that the proteins
are stable during the simulation. Gyration radius is an
indicative of the level of compaction in the structure,
i.e., how folded or unfolded is the protein. H bond for-
mation/deformation factor represents the number of
hydrogen bonds formed or broken during molecular
simulation. During 10 ns of simulation, this number
was almost constant indicating the stability of the
molecular structures. Figures 4, 5 and 6 represents
simulation analysis of PfCelTOS, IL-2-(GGGGS)3-
PfCelTOS and Co1-(AEEEK)3- IL-2-(GGGGS)3-PfCel-
TOS, respectively, that validated the accuracy of our
designed fusion protein structure.
Structure validation of predicted models
To validate the modeled structures, Ramachandran maps
were drawn before as well as after MD simulation and
structures were analyzed using RAMPAGE Ramachan-
dran Plot Assessment. The Ramchandran plot analysis
obtained by RAMPAGE Ramachandran Plot Assessment
is summarized in Table 4 and the plots are provided in
Fig. 7. This provides an insight into the correctness of
the modeled structures. As it’s obvious Co1-(AEEEK)3-
IL-2-(GGGGS)3-PfCelTOS has a well modeled structure
in terms of RAMPAGE Ramachandran Plot Assessment.
Comparison of predicted structures before and after MD
simulation
3D Structures of PfCelTOS and fusion constructs were
also investigated after MD simulation (Fig. 8). Overlay-
ing of 3D structure of PfCelTOS and designed fusion
proteins before and after MD simulation showed that
the predicted structures are constantly stable and the
selected linkers are able to separate the domains of de-
signed fusion constructs effectively. As it’s obvious,
rigid linker ensures the separation of domains and car-
rier and leads to the better presentation of construct to
human M-like cells (Fig. 9). Structural comparison of
predicted models of PfCelTOS and Co1-(AEEEK)3−
IL-2-(GGGGS)3-PfCelTOS, obtained after molecular
dynamics simulations is shown in Fig. 10. This com-
parison indicates the proper folding of PfCelTOS in
fusion construct.
Conclusion
The procedure of our study (as shown in Fig. 1) helps to
rapid analysis of designed fusion constructs before ini-
tializing the recombinant fusion protein lab experiments.
As it is obvious, this procedure is fast, inexpensive (since
all the servers are free) and simple, especially for inex-
pert users in this field.
In silico study of Co1-(AEEEK)3- IL-2-(GGGGS)3-
PfCelTOS structure through this procedure revealed that
designed construction is suitable for fusion protein ex-
pression in edible host cells for oral delivery. Flexible
linker separates PfCelTOS and IL-2 domains effectively
to maintain their proper individual three dimensional
structures and allows them to move independently of
one another. On the other hand, rigid linker ensures the
separation of fusion protein and carrier and lead to the
better presentation of fusion construct to human M-like
cells. Therefore, data reported in this paper represents
the first step toward developing of an oral vaccine candi-
date against malaria infection.
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